BMY

Bristol-Myers Squibb Co

66.82

Sep 04 • 3:59 PM ET -1.27 (-1.87%)

66.99

Aftermarket • 4:30 PM ET +0.17 (0.25%)

Healthcare Drug Manufacturers - General USA Large NYSE

Peers: PFE MRK ABBV JNJ LLY AZN NVS AMGN GILD GSK

| Held by: VTI SCHD VOO IVV SPY VTV XLV VYM HDV COWZ

Scroll to Statements

Index	S&P 500
Market Cap	136.49B
Enterprise Value	170.48B
Income	9.28B
Sales	49.20B
Book/sh	10.92
Cash/sh	5.42
Dividend Est.	2.34 (3.50%)
Dividend TTM	2.51 (3.76%)
Dividend Ex-Date	Jul 02, 2026
Dividend Gr. 3/5Y	4.37% 6.24%
Payout	71.98%
Employees	32500
IPO	Jul 05, 1929

P/E	14.72
Forward P/E	10.20
PEG	-
P/S	2.77
P/B	6.12
P/C	12.33
P/FCF	11.93
EV/EBITDA	8.88
EV/Sales	3.47
Quick Ratio	1.38
Current Ratio	1.53
Debt/Eq	2.02
LT Debt/Eq	1.96
Option/Short	Yes / Yes

EPS (ttm)	4.54
EPS next Y	6.55
EPS next Q	1.72
EPS this Y	12.67%
EPS next Y	-5.44%
EPS next 5Y	-2.89%
EPS past 3/5Y	5.47% -
Sales past 3/5Y	1.45% 2.54%
EPS Y/Y TTM	83.17%
Sales Y/Y TTM	3.13%
EPS Q/Q	49.96%
Sales Q/Q	6.22%
Earnings	Jul 30 BMO
EPS/Sales Surpr.	27.73% 10.51%

Insider Own	0.32%
Insider Trans	-0.46%
Inst Own	85.13%
Inst Trans	0.54%
ROA	10.18%
ROE	46.70%
ROIC	14.03%
Gross Margin	66.64%
Oper. Margin	32.35%
Profit Margin	18.87%
SMA20	0.94%
SMA50	6.23%
SMA200	14.93%
Trades

Shs Outstand	2.04B
Shs Float	2.04B
Short Float	2.25%
Short Ratio	3.99
Short Interest	45.85M
52W High	68.64 -2.65%
52W Low	42.52 57.15%
Volatility	1.79% 2.06%
ATR (14)	1.51
RSI (14)	56.48
Beta	0.18
Rel Volume	0.40
Avg Volume	11.49M
Volume	4,585,159

Perf Week	0.36%
Perf Month	4.16%
Perf Quarter	16.68%
Perf Half Y	10.83%
Perf YTD	23.88%
Perf Year	43.11%
Perf 3Y	7.74%
Perf 5Y	1.84%
Perf 10Y	18.58%
Recom	2.45
Target Price	66.04
Prev Close	68.09
Price	66.82
Change %	-1.87%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-26	Upgrade	Argus	Hold → Buy	$75
Feb-25-26	Initiated	RBC Capital Mkts	Sector Perform	$60
Feb-20-26	Initiated	Barclays	Overweight	$75
Jan-07-26	Upgrade	UBS	Neutral → Buy	$65
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy	$61
Dec-12-25	Upgrade	Guggenheim	Neutral → Buy	$62
Nov-13-25	Initiated	Scotiabank	Sector Perform	$45
Aug-05-25	Downgrade	Daiwa Securities	Outperform → Neutral	$42
Apr-22-25	Initiated	Piper Sandler	Overweight
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$55
Dec-16-24	Upgrade	Jefferies	Hold → Buy	$70
Dec-10-24	Resumed	BofA Securities	Neutral	$63
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-13-24	Upgrade	Daiwa Securities	Neutral → Outperform
Nov-12-24	Upgrade	Leerink Partners	Market Perform → Outperform	$73
Oct-25-24	Downgrade	Citigroup	Buy → Neutral	$75 → $55
Oct-17-24	Initiated	Bernstein	Mkt Perform	$56
Jul-29-24	Downgrade	Barclays	Overweight → Equal Weight	$41
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral	$77 → $54

Show Previous Ratings

Sep-03-26 12:07PM	Is Merck Stock Pricing In A Post-Keytruda Future Too Soon? (Trefis)
12:00PM	Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug (Barrons.com)
11:54AM	ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care? (Trefis)
09:00AM	Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds (ACCESSWIRE)
01:51AM	Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services (Barrons.com)
04:55PM	Loading…
Sep-02-26 04:55PM	Amgen Stock Signals Its Confidence. The Market Agrees. (Trefis)
02:19PM	Can AI Save Pfizer Stock Before Its Patent Cliff Hits? (Trefis)
01:16PM	How Did Merck Stock Beat The Market With Slowing Sales? (Trefis)
08:32AM	Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive)
08:00AM	Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials (Proactive)
Sep-01-26 12:14AM	Novartis Pauses Autoimmune Cell Therapy Studies After Deaths (The Wall Street Journal)
Aug-31-26 01:38PM	Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns (BioPharma Dive)
11:39AM	Cocrystal Pharma: The Strategic Reset Investors May Be Missing (Exec Edge)
07:00AM	Jefferies starts biopharma firm Braveheart at Buy after IPO (Investing.com)
Aug-29-26 11:00AM	Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 (Business Wire)
02:35PM	Loading…
Aug-28-26 02:35PM	Can Merck Stock Outrun Its Pipeline? (Trefis)
05:47AM	Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers (Investor's Business Daily)
Aug-27-26 08:19PM	Amgen Stock Signals Its Confidence. The Market Agrees. (Trefis)
01:01PM	Is Merck Stock Reaching A Valuation Ceiling At 6x Sales? (Trefis)
10:25AM	Can Cost Cuts And 2030 Targets Really Save Pfizer Stock? (Trefis)
Aug-26-26 03:41PM	Has AbbVie Stock Become Too Expensive to Buy? (Trefis)
Aug-25-26 04:49PM	The Hidden Engine That Could Drive Walt Disney Stock Higher (Trefis)
Aug-24-26 02:36PM	Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition (Trefis)
Aug-21-26 01:48PM	Most Of What Moves AbbVie Stock Has Nothing To Do With The Market (Trefis)
05:30AM	Shareholder pressures Capricor; Lilly dives deeper into vaccines (BioPharma Dive)
Aug-20-26 01:27PM	Merck Stock Ran On A Checklist Published In Advance (Trefis)
12:54PM	Pfizer Stock Is A Race Between New Drugs And Old Patents (Trefis)
05:59AM	Why Is Merck Stock Still Undervalued After An 80% Surge? (Trefis)
Aug-19-26 03:40PM	Is AbbVie Stock About To Break Out Again? (Trefis)
07:34AM	Bristol Myers Squibb to build $2.3B manufacturing campus in Houston (Manufacturing Dive)
05:30AM	Loading…
05:30AM	The Key to Pharma M&A: Never Shopping Hungry (The Wall Street Journal)
Aug-18-26 07:13AM	AstraZenecas win in lung cancer; Sandoz inks a China deal (BioPharma Dive)
07:13AM	AstraZeneca scores in lung cancer; Sandoz inks a China deal (BioPharma Dive)
Aug-14-26 05:22PM	AbbVie Defends Its Turf, But Leaves One Big Question Open (Trefis)
08:02AM	Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene (BioPharma Dive)
05:51AM	BMS builds big in Texas; Regeneron backs would-be rival (Pharma Voice)
05:28AM	Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers (BioPharma Dive)
Aug-13-26 05:12PM	U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse (Business Wire)
01:54PM	Appeals court revives $6.7B lawsuit against Bristol Myers Squibb (Quartz)
01:54PM	Appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb over delayed drug approvals (Quartz)
12:10PM	The Sharpest Exchanges From ABBV's Earnings Call (Trefis)
08:00AM	Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration (PR Newswire)
Aug-12-26 04:49PM	How ABBV Stock Moved Away From Its Peer Group (Trefis)
03:17PM	Amgen Stock And The Price Of A Promise (Trefis)
12:00AM	How AstraZenecas $400bn deal unravelled (Financial Times)
Aug-11-26 05:38PM	$49 Billion In Payouts, A Lagging Stock: The PFE Trade-Off (Trefis)
12:03PM	BMS Plans $2.3B Houston Manufacturing Campus (CRE Daily)
07:25AM	BMS banks on Texas for $2.3bn multi-modal manufacturing facility (Pharmaceutical Technology)
05:30AM	Healthcare Investing Is Now an AI Short in Disguise (The Wall Street Journal)
Aug-10-26 04:11PM	Pharmaceutical giant to build $2.3B plant, create 500 jobs in Texas (USA TODAY)
01:37PM	Bristol Myers Squibb to build $2.3 billion Houston campus (Quartz)
10:27AM	Bristol Myers Squibb plans $2.3 billion Houston manufacturing campus (InvestorsHub)
09:01AM	Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas (Business Wire)
Aug-07-26 12:36PM	Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. (Barrons.com)
11:30AM	These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks (Barrons.com)
05:20AM	Why Big Pharma is chasing the industrys most-powerful supercomputer (Pharma Voice)
01:00AM	Why FTSE companies are heading for the exit (The Telegraph)
01:00AM	The 20-year exodus hollowing out the London stock market (The Telegraph)
01:00AM	How the FTSE became a departure lounge for British companies (The Telegraph)
Aug-06-26 06:01AM	Schrödinger and BMS expand partnership to deploy AI for drug discovery (Pharmaceutical Technology)
05:26AM	What the AstraZeneca-BMS rumors reveal about pharma megamergers (Pharma Voice)
Aug-05-26 05:23PM	Why PFE Stock Hands You So Much Cash Right Now (Trefis)
04:01PM	Cardiac drug developer Braveheart banks more than $382M in IPO (BioPharma Dive)
12:17PM	AstraZeneca-Bristol Myers $400B Merger Buzz Cools After Report Denies Talks There Never Was A Deal To Be Done (Stocktwits)
10:01AM	AZN rebounds after report dismisses AstraZeneca-Bristol Myers merger speculation (InvestorsHub)
09:40AM	Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls (The Fly)
09:11AM	AstraZeneca and Bristol Myers Squibb merger talks denied (Quartz)
09:05AM	Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative Deals (The Wall Street Journal)
09:00AM	AZN spikes 6% after report it denies AstraZeneca-BMS merger talks (Investing.com)
08:10AM	AstraZeneca stock jumps and Bristol Myers shares fall on report of 'no discussions' (MarketWatch)
06:49AM	Elon Musk Has Lost the Midas Touch as AI Spending Booms (Barrons.com)
Aug-04-26 02:45PM	AstraZeneca Faces Fresh Pressure As $400B Bristol Myers Deal Talks Reportedly Persist (Stocktwits)
10:32AM	Brokers split on AstraZeneca merger talk as shares recover some ground (Proactive)
07:53AM	AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open (Barrons.com)
05:30AM	How a pharma megamerger could squelch R&D (Axios)
01:30AM	More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not (Barrons.com)
Aug-03-26 09:46PM	Why Did AMZN, SNOW, BMY Stocks Surge To 52-Week Highs Today? (Stocktwits)
07:14PM	$49 Billion In Payouts, A Lagging Stock: The Pfizer Trade-Off (Trefis)
05:26PM	MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus These FDA Decisions Could Shape August Trading (Stocktwits)
05:05PM	AbbVie's Growth Now Leans On A Single Molecule (Trefis)
04:29PM	AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks (GuruFocus.com)
01:27PM	AstraZeneca Eyes a Pharma Megamerger Nobody Asked For (Moby)
12:40PM	AstraZeneca Investors See Little Logic in Bristol Tie-Up (Bloomberg)
12:03PM	AstraZeneca shares slump after $400bn BMS merger rumours (Pharmaceutical Technology)
11:52AM	Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen? (Investing.com)
09:27AM	Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca (Investopedia)
09:20AM	AstraZeneca Stock Nosedives On Mega-Merger Rumor (Investor's Business Daily)
09:08AM	Medicus Pharma CMO to lead Antev's Teverelix clinical programme (Proactive)
08:26AM	AstraZeneca, Bristol Myers Squibb exploring merger talks (Quartz)
08:04AM	AstraZeneca Weighs a Deal Its CEO Said It Didn't Need (GuruFocus.com)
08:03AM	5 Things to Know Before the Stock Market Opens on Monday (Investopedia)
07:50AM	Wall St futures gain on Mideast deal hopes; healthcare in focus (Reuters)
07:02AM	Analysts baffled by AstraZeneca's interest in Bristol Myers Squibb (Proactive)
06:48AM	Palantir, Micron, SK Hynix, Alibaba, and More Stocks That Explain Today's Market (Barrons.com)
06:43AM	AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled. (MarketWatch)
05:54AM	Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca (Barrons.com)
05:45AM	Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy (Pharmaceutical Technology)
04:26AM	U.S. Stock Futures Rise, Oil Falls as U.S. Shifts Toward Diplomacy with Iran (The Wall Street Journal)
04:06AM	AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks (The Wall Street Journal)
03:24AM	AstraZeneca shares slide 7% on talks to buy Bristol Myers Squibb (Proactive)

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

CEO & ChairmanDr. Christopher S. Boerner Ph.D.

Executive VP & CFOMr. David V. Elkins

Executive VP and Chief Digital & Technology OfficerMr. Greg Meyers

Executive VP & Chief Commercialization OfficerMr. Adam Lenkowsky

Executive VPMr. Cristian Massacesi M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Short Bartie Wendy	EVP, Corporate Affairs	Sep 01 '26	Option Exercise	66.92	1,236	82,713	13,317	Sep 03 04:12 PM
Holzer Phil M	SVP and Controller	Aug 25 '26	Sale	67.50	500	33,750	16,862	Aug 26 04:17 PM
Holzer Phil M	Officer	Aug 25 '26	Proposed Sale	67.50	500	33,750		Aug 25 11:03 AM
Massacesi Cristian	EVP,Chief Med Offr,Head of Dev	Aug 01 '26	Option Exercise	0.00	51,172	0	51,172	Aug 04 04:10 PM
Gallman Cari	EVP, General Counsel	Aug 01 '26	Option Exercise	0.00	1,061	0	14,192	Aug 04 04:07 PM
Haller Julia A	Director	Jun 15 '26	Option Exercise	53.76	20,460	1,099,930	34,079	Jun 16 04:07 PM
Short Bartie Wendy	EVP, Corporate Affairs	Jun 03 '26	Option Exercise	0.00	8,040	0	15,957	Jun 05 04:10 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	May 01 '26	Option Exercise	0.00	1,373	0	20,508	May 05 05:11 PM
Shanahan Karin	EVP, Chief Supply Chain & Ops	Apr 01 '26	Option Exercise	0.00	3,307	0	27,580	Apr 02 04:30 PM
Elkins David V	EVP, Chief Financial Officer	Apr 01 '26	Sale	61.67	30,000	1,850,016	159,248	Apr 02 04:29 PM
Elkins David V	Officer	Apr 01 '26	Proposed Sale	61.69	30,000	1,850,645		Apr 01 04:32 PM
Short Bartie Wendy	EVP, Corporate Affairs	Mar 10 '26	Option Exercise	0.00	5,883	0	10,952	Mar 12 04:22 PM
Shanahan Karin	EVP, Chief Supply Chain & Ops	Mar 10 '26	Option Exercise	0.00	25,501	0	39,120	Mar 12 04:21 PM
Plenge Robert M	EVP, Chief Research Officer	Mar 10 '26	Option Exercise	0.00	17,501	0	31,600	Mar 12 04:20 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Mar 10 '26	Option Exercise	0.00	25,892	0	44,330	Mar 12 04:19 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	Mar 10 '26	Option Exercise	0.00	24,071	0	26,104	Mar 12 04:18 PM
Holzer Phil M	SVP and Controller	Mar 10 '26	Option Exercise	0.00	6,191	0	20,475	Mar 12 04:17 PM
Hoch Lynelle	President, Cell Therapy Org.	Mar 10 '26	Option Exercise	0.00	8,192	0	12,217	Mar 12 04:17 PM
Gallman Cari	EVP, General Counsel	Mar 10 '26	Option Exercise	0.00	6,980	0	17,039	Mar 12 04:16 PM
Poole Ahn Amanda	EVP, Chief People Officer	Mar 10 '26	Option Exercise	0.00	6,436	0	10,718	Mar 12 04:15 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Mar 10 '26	Option Exercise	0.00	71,537	0	47,382	Mar 12 04:14 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10 '26	Option Exercise	0.00	62,982	0	222,773	Mar 12 04:13 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01 '26	Option Exercise	0.00	2,543	0	22,261	Feb 03 04:40 PM
Hickey Benjamin	President, RayzeBio Org.	Feb 01 '26	Option Exercise	0.00	10,079	0	18,868	Feb 03 04:39 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Nov 01 '25	Option Exercise	0.00	2,964	0	2,964	Nov 04 05:18 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Nov 01 '25	Option Exercise	0.00	6,281	0	22,383	Nov 04 05:15 PM
Shanahan Karin	EVP, Chief Supply Chain & Ops	Nov 01 '25	Option Exercise	0.00	6,281	0	20,078	Nov 04 05:13 PM
Gallman Cari	EVP, General Counsel	Oct 02 '25	Option Exercise	0.00	4,558	0	13,398	Oct 06 05:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMY

Bristol-Myers Squibb Co

Upgrade your Finviz experience